ArticleJournal of hematology2026
Evaluating Hemoglobin Thresholds for Blood Transfusions in Oncology Patients Admitted to the Intensive Care Unit.
Article in Journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the intensive care unit (ICU), up to 90% of patients develop anemia during their stay. However, evidence regarding transfusion practices in oncology patients requiring ICU-level care is limited. This study aimed to compare mortality, survival rate, and readmissions across three hemoglobin thresholds of transfusion (low < 7 g/dL, intermediate 7-8 g/dL, and high > 8 g/dL) among these patients. Methods: A retrospective analysis of 561 patients with cancer admitted to the ICU who received blood transfusions from 2017 to 2023 was performed. Univariate and multivariate analyses were utilized to compare three hemoglobin thresholds of transfusion. A P ≤ 0.05 was considered significant. Results: Of 561 patients, the transfusion burden was greater in the low threshold cohort (46.6%), followed by intermediate (29.3%) and high (24.1%) thresholds. The low threshold cohort required a longer duration of mechanical ventilation compared to the high threshold (P ≤ 0.03). The readmission rate was highest in the low threshold cohort compared to the others (30-day: 23.4% vs 11% vs 16.3%; 90-day: 3.1% vs 1.2% vs 2.2%). Mortality risk was elevated in patients transfused at high thresholds compared with those transfused at low thresholds (odds ratio (OR), 1.893; 95% confidence interval (CI), 1.093-3.281; P < 0.05), and mortality did not differ between the low and intermediate thresholds (P > 0.05). The intermediate threshold showed the highest survival probability, and the high threshold had the worst survival. Conclusions: In patients with malignancy admitted to the ICU, transfusions administered at levels < 7 g/dL were associated with a greater transfusion burden, longer mechanical ventilation, and higher 30- and 90-day readmissions. The high threshold was associated with poor survival. These findings highlight the need for prospective studies in ICU oncology on the blood transfusion threshold.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.